O	0	1	A
O	2	12	randomized
O	13	23	controlled
O	24	29	trial
O	30	32	on
O	33	36	the
O	37	43	effect
O	44	46	of
O	47	48	a
B-intervention	49	55	silver
I-intervention	56	78	carboxymethylcellulose
I-intervention	79	87	dressing
O	88	90	on
B-condition	91	99	surgical
I-condition	100	104	site
I-condition	105	115	infections
O	116	121	after
O	122	128	breast
O	129	135	cancer
O	136	143	surgery
O	143	144	.

O	145	148	The
O	149	158	incidence
O	159	161	of
O	162	170	surgical
O	171	175	site
O	176	186	infections
O	187	188	(
O	188	192	SSIs
O	192	193	)
O	194	199	after
O	200	206	breast
O	207	213	cancer
O	214	221	surgery
O	222	224	is
O	225	235	relatively
O	236	240	high
O	240	241	;
O	242	249	ranging
O	250	254	from
O	255	256	3
O	257	259	to
O	260	262	19
O	262	263	%
O	263	264	.

O	265	268	The
O	269	273	role
O	274	276	of
O	277	282	wound
O	283	292	dressings
O	293	295	in
O	296	299	the
O	300	310	prevention
O	311	313	of
O	314	317	SSI
O	318	323	after
O	324	330	breast
O	331	337	cancer
O	338	345	surgery
O	346	348	is
O	349	356	unclear
O	356	357	.

O	358	362	This
O	363	368	study
O	369	377	compares
O	378	379	a
O	380	386	silver
O	387	409	carboxymethylcellulose
O	410	418	dressing
O	419	420	(
O	420	427	AQUACEL
O	428	430	Ag
O	431	439	Surgical
O	440	441	(
O	441	448	Aquacel
O	448	449	)
O	450	454	with
O	455	463	standard
O	464	469	wound
O	470	478	dressing
O	479	481	in
O	482	485	SSI
O	486	490	rate
O	491	496	after
O	497	503	breast
O	504	510	cancer
O	511	518	surgery
O	518	519	.

O	520	521	A
O	522	528	single
O	528	529	-
O	529	535	centre
O	536	546	randomized
O	547	557	controlled
O	558	563	trial
O	564	569	among
O	570	575	women
B-age	576	577	≥
I-age	577	579	18
I-age	580	585	years
O	585	586	,
B-eligibility	587	596	diagnosed
I-eligibility	597	601	with
I-eligibility	602	608	breast
I-eligibility	609	615	cancer
I-eligibility	615	616	,
I-eligibility	617	627	undergoing
I-eligibility	628	634	breast
I-eligibility	635	645	conserving
I-eligibility	646	648	or
I-eligibility	649	657	ablative
I-eligibility	658	665	surgery
O	665	666	,
O	667	670	was
O	671	680	conducted
O	681	683	in
O	684	685	a
O	686	694	combined
O	695	697	in
O	698	701	and
O	702	712	outpatient
O	713	720	setting
O	720	721	.

O	722	725	The
O	726	738	intervention
O	739	742	was
O	743	746	the
O	747	750	use
O	751	753	of
O	754	761	Aquacel
O	761	762	,
O	763	771	compared
O	772	776	with
O	777	785	standard
O	786	791	gauze
O	792	800	dressing
O	800	801	.

O	802	809	Primary
O	810	817	outcome
O	818	825	measure
O	826	829	was
B-outcome-Measure	830	833	SSI
I-outcome-Measure	834	843	following
I-outcome-Measure	844	847	CDC
I-outcome-Measure	848	856	criteria
O	856	857	.

O	858	859	A
O	860	865	total
O	866	868	of
B-total-participants	869	872	230
O	873	881	patients
O	882	886	were
O	887	895	analysed
O	895	896	:
B-intervention-participants	897	900	106
O	901	903	in
O	904	907	the
O	908	915	Aquacel
O	916	921	group
O	922	925	and
B-control-participants	926	929	124
B-control	930	938	controls
O	938	939	.

B-iv-bin-abs	940	945	Seven
O	946	954	patients
O	955	956	(
B-iv-bin-percent	956	957	6
I-iv-bin-percent	957	958	.
I-iv-bin-percent	958	959	6
I-iv-bin-percent	959	960	%
O	960	961	)
B-outcome	962	971	developed
I-outcome	972	975	SSI
O	976	978	in
O	979	982	the
O	983	990	Aquacel
O	991	996	group
O	997	1000	and
B-cv-bin-abs	1001	1003	16
O	1004	1012	patients
O	1013	1014	(
B-cv-bin-percent	1014	1016	12
I-cv-bin-percent	1016	1017	.
I-cv-bin-percent	1017	1018	9
I-cv-bin-percent	1018	1019	%
O	1019	1020	)
O	1021	1023	in
O	1024	1027	the
O	1028	1035	control
O	1036	1041	group
O	1042	1043	(
O	1043	1045	RR
O	1046	1047	0
O	1047	1048	.
O	1048	1050	51
O	1051	1052	[
O	1052	1054	95
O	1054	1055	%
O	1056	1066	Confidence
O	1067	1075	Interval
O	1076	1077	(
O	1077	1079	CI
O	1079	1080	)
O	1080	1081	:
O	1082	1083	0
O	1083	1084	.
O	1084	1086	22
O	1086	1087	-
O	1087	1088	1
O	1088	1089	.
O	1089	1091	20
O	1091	1092	]
O	1092	1093	;
O	1094	1095	p
O	1096	1097	=
O	1098	1099	0
O	1099	1100	.
O	1100	1103	112
O	1103	1104	;
O	1105	1113	adjusted
O	1114	1116	OR
O	1117	1118	0
O	1118	1119	.
O	1119	1121	49
O	1122	1123	[
O	1123	1124	0
O	1124	1125	.
O	1125	1127	19
O	1127	1128	-
O	1128	1129	1
O	1129	1130	.
O	1130	1132	25
O	1132	1133	]
O	1134	1135	p
O	1136	1137	=
O	1138	1139	0
O	1139	1140	.
O	1140	1143	135
O	1143	1144	)
O	1144	1145	)
O	1145	1146	.

O	1147	1156	Unplanned
O	1157	1168	exploratory
O	1169	1177	subgroup
O	1178	1186	analysis
O	1187	1189	of
O	1190	1196	breast
O	1197	1207	conserving
O	1208	1215	surgery
O	1216	1224	patients
O	1225	1231	showed
O	1232	1236	that
B-outcome	1237	1240	SSI
I-outcome	1241	1245	rate
O	1246	1249	was
B-iv-bin-abs	1250	1251	1
O	1251	1252	/
B-intervention-participants	1252	1254	56
O	1255	1256	(
B-iv-bin-percent	1256	1257	1
I-iv-bin-percent	1257	1258	.
I-iv-bin-percent	1258	1259	8
I-iv-bin-percent	1259	1260	%
O	1260	1261	)
O	1262	1264	in
O	1265	1268	the
O	1269	1276	Aquacel
O	1277	1282	group
O	1283	1285	vs
O	1285	1286	.
B-cv-bin-abs	1287	1288	7
O	1288	1289	/
B-control-participants	1289	1291	65
O	1292	1293	(
B-cv-bin-percent	1293	1295	10
I-cv-bin-percent	1295	1296	.
I-cv-bin-percent	1296	1297	8
I-cv-bin-percent	1297	1298	%
O	1298	1299	)
O	1300	1302	in
O	1303	1311	controls
O	1311	1312	;
O	1313	1321	adjusted
O	1322	1324	OR
O	1325	1326	0
O	1326	1327	.
O	1327	1329	15
O	1330	1331	[
O	1331	1332	0
O	1332	1333	.
O	1333	1335	02
O	1335	1336	-
O	1336	1337	1
O	1337	1338	.
O	1338	1340	31
O	1340	1341	]
O	1342	1343	p
O	1344	1345	=
O	1346	1347	0
O	1347	1348	.
O	1348	1351	087
O	1351	1352	.

O	1353	1356	The
O	1357	1364	Aquacel
O	1365	1370	group
O	1371	1377	showed
O	1378	1384	better
B-outcome	1385	1392	patient
I-outcome	1393	1405	satisfaction
O	1406	1407	(
O	1407	1413	median
B-iv-cont-median	1414	1415	8
O	1416	1418	vs
O	1418	1419	.
B-cv-cont-median	1420	1421	7
O	1422	1424	on
O	1425	1426	a
O	1427	1436	Numerical
O	1437	1443	Rating
O	1444	1449	Scale
O	1449	1450	,
O	1451	1452	p
O	1453	1454	=
O	1455	1456	0
O	1456	1457	.
O	1457	1460	006
O	1460	1461	)
O	1461	1462	,
O	1463	1468	fewer
B-outcome	1469	1477	dressing
I-outcome	1478	1485	changes
I-outcome	1486	1492	within
I-outcome	1493	1495	48
I-outcome	1496	1501	hours
O	1501	1502	(
O	1502	1510	adjusted
O	1511	1513	OR
O	1514	1515	0
O	1515	1516	.
O	1516	1518	12
O	1519	1520	[
O	1520	1521	0
O	1521	1522	.
O	1522	1524	05
O	1524	1525	-
O	1525	1526	0
O	1526	1527	.
O	1527	1529	27
O	1529	1530	]
O	1531	1532	p
O	1532	1533	<
O	1533	1534	0
O	1534	1535	.
O	1535	1538	001
O	1538	1539	)
O	1539	1540	,
O	1541	1546	fewer
B-outcome	1547	1549	re
I-outcome	1549	1550	-
I-outcome	1550	1560	operations
O	1561	1562	(
B-iv-bin-percent	1562	1563	0
I-iv-bin-percent	1563	1564	%
O	1565	1567	vs
O	1567	1568	.
B-cv-bin-percent	1569	1570	3
I-cv-bin-percent	1570	1571	.
I-cv-bin-percent	1571	1572	2
I-cv-bin-percent	1572	1573	%
O	1573	1574	,
O	1575	1576	p
O	1577	1578	=
O	1579	1580	0
O	1580	1581	.
O	1581	1584	062
O	1584	1585	)
O	1585	1586	,
O	1587	1590	and
O	1591	1596	lower
B-outcome	1597	1601	mean
I-outcome	1602	1607	wound
I-outcome	1607	1608	-
I-outcome	1608	1615	related
I-outcome	1616	1625	treatment
I-outcome	1626	1631	costs
O	1631	1632	,
O	1633	1637	both
O	1638	1640	in
O	1641	1642	a
O	1643	1647	high
O	1648	1649	(
B-iv-cont-mean	1649	1650	€
I-iv-cont-mean	1650	1653	265
I-iv-cont-mean	1653	1654	.
I-iv-cont-mean	1654	1656	42
O	1657	1658	(
O	1658	1660	SD
O	1661	1662	=
B-iv-cont-sd	1663	1666	908
O	1666	1667	)
O	1668	1670	vs
O	1670	1671	.
B-cv-cont-mean	1672	1673	€
I-cv-cont-mean	1673	1676	470
I-cv-cont-mean	1676	1677	.
I-cv-cont-mean	1677	1679	65
O	1680	1681	(
O	1681	1683	SD
O	1684	1685	=
B-cv-cont-sd	1686	1690	1223
O	1690	1691	)
O	1692	1693	[
O	1693	1694	p
O	1694	1695	<
O	1695	1696	0
O	1696	1697	.
O	1697	1700	001
O	1700	1701	]
O	1701	1702	)
O	1703	1706	and
O	1707	1710	low
O	1711	1712	(
B-iv-cont-mean	1712	1713	€
I-iv-cont-mean	1713	1715	59
I-iv-cont-mean	1715	1716	.
I-iv-cont-mean	1716	1718	12
O	1719	1720	(
O	1720	1722	SD
O	1723	1724	=
B-iv-cont-sd	1725	1728	129
O	1728	1729	)
O	1730	1732	vs
O	1732	1733	.
B-cv-cont-mean	1734	1735	€
I-cv-cont-mean	1735	1737	67
I-cv-cont-mean	1737	1738	.
I-cv-cont-mean	1738	1740	55
O	1741	1742	(
O	1742	1744	SD
O	1745	1746	=
B-cv-cont-sd	1747	1750	172
O	1750	1751	)
O	1752	1753	[
O	1753	1754	p
O	1754	1755	<
O	1755	1756	0
O	1756	1757	.
O	1757	1760	001
O	1760	1761	]
O	1761	1762	)
B-outcome	1763	1775	attributable
I-outcome	1776	1781	costs
I-outcome	1782	1784	of
I-outcome	1785	1788	SSI
I-outcome	1789	1794	model
O	1794	1795	.

O	1796	1798	In
O	1799	1803	this
O	1804	1814	randomized
O	1815	1825	controlled
O	1826	1831	trial
O	1832	1834	in
O	1835	1840	women
O	1841	1851	undergoing
O	1852	1859	surgery
O	1860	1863	for
O	1864	1870	breast
O	1871	1877	cancer
O	1877	1878	,
O	1879	1882	the
O	1883	1886	use
O	1887	1889	of
O	1890	1897	AQUACEL
O	1898	1900	Ag
O	1901	1909	Surgical
O	1910	1915	wound
O	1916	1924	dressing
O	1925	1928	did
O	1929	1932	not
O	1933	1946	significantly
O	1947	1953	reduce
O	1954	1957	the
O	1958	1968	occurrence
O	1969	1971	of
O	1972	1976	SSIs
O	1977	1985	compared
O	1986	1988	to
O	1989	1997	standard
O	1998	2003	gauze
O	2004	2012	dressing
O	2012	2013	.

O	2014	2017	The
O	2018	2021	use
O	2022	2024	of
O	2025	2032	Aquacel
O	2033	2041	resulted
O	2042	2044	in
O	2045	2058	significantly
O	2059	2067	improved
O	2068	2075	patient
O	2076	2088	satisfaction
O	2088	2089	,
O	2090	2097	reduced
O	2098	2106	dressing
O	2107	2114	changes
O	2115	2118	and
O	2119	2126	reduced
O	2127	2132	wound
O	2132	2133	-
O	2133	2140	related
O	2141	2146	costs
O	2146	2147	.
O	2148	2151	www
O	2151	2152	.
O	2152	2165	trialregister
O	2165	2166	.
O	2166	2168	nl
O	2168	2169	:
O	2170	2177	NTR5840
O	2177	2178	.
